Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Trial details
- Registry ID
- NCT07290569
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque PsoriasisNCT07290569 | ORKA | Phase 2 | Active not recruiting | 2026-10-21Actual |
| An Open-Label Extension Study of ORKA-001 in Participants With Plaque PsoriasisNCT07449702 | ORKA | Phase 2 | Recruiting | 2030-05Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |